首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >VEGF-trap Aflibercept Significantly Improves Long-term Graft Survival in High-risk Corneal Transplantation
【24h】

VEGF-trap Aflibercept Significantly Improves Long-term Graft Survival in High-risk Corneal Transplantation

机译:VEGF捕获剂Aflibercept显着提高高危角膜移植的长期移植存活率

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background. Graft failure because of immune rejection remains a significant problem in organ transplantation, and lymphatic and blood vessels are important components of the afferent and efferent arms of the host alloimmune response, respectively. We compare the effect of antihemangiogenic and antilymphangiogenic therapies on alloimmunity and graft survival in a murine model of high-risk corneal transplantation. Methods. Orthotopic corneal transplantation was performed in hemevascularized and lymph-vascularized high-risk host beds, and graft recipients received subconjunctival vascular endothelial growth factor (VEGF)-trap, anti-VEGF-C, sVEGFR-3, or no treatment, beginning at the time of surgery. Fourteen days after transplantation, graft hemeangiogenesis and lymphangiogenesis were evaluated by immunohistochemistry. The frequencies of Th1 cells in regional lymphoid tissue and graft-infiltrating immune cells were evaluated by flow cytometry. Long-term allograft survival was compared using Kaplan-Meier curves. Results. VEGF-trap significantly decreased graft hemangiogenesis as compared to the control group and was most effective in reducing the frequency of graft-infiltrating immune cells. Anti-VEGF-C and sVEGFR3 significantly decreased graft lymphangiogenesis and lymphoid Th1 cell frequencies as compared to control. VEGF-trap (72%), anti-VEGF-C (25%), and sVEGFR-3 (11%) all significantly improved in the 8-week graft survival compared to control (0%), although VEGF-trap was significantly more effective than both anti-VEGF-C (P < 0.05) and sVEGFR-3 (P < 0.05). Conclusion. In a clinically relevant model of high-risk corneal transplantation in which blood and lymphatic vessels are present and treatment begins at the time of transplantation, VEGF-trap is significantly more effective in improving long-term graft survival as compared to anti-VEGF-C and sVEGFR-3, but all approaches improve survival when compared to untreated control.
机译:背景。由于免疫排斥引起的移植失败仍然是器官移植中的重要问题,淋巴管和血管分别是宿主同种异体免疫反应的传入和传出臂的重要组成部分。我们在高风险角膜移植的小鼠模型中比较了抗血液生成和抗淋巴管生成疗法对同种免疫和移植物存活的影响。方法。原位角膜移植是在有血管和淋巴血管化的高危宿主床中进行的,移植接受者从那时开始接受结膜下血管内皮生长因子(VEGF)捕获,抗VEGF-C,sVEGFR-3或不接受任何治疗的手术。移植后第十四天,通过免疫组织化学评估移植物的血管生成和淋巴管生成。通过流式细胞术评估局部淋巴组织和移植物浸润免疫细胞中Th1细胞的频率。使用Kaplan-Meier曲线比较同种异体移植的长期存活率。结果。与对照组相比,VEGF-trap显着降低了移植血管的生成,并且在减少移植物浸润免疫细胞的频率方面最有效。与对照组相比,抗-VEGF-C和sVEGFR3显着降低了移植淋巴管生成和淋巴样Th1细胞频率。 VEGF-trap(72%),抗VEGF-C(25%)和sVEGFR-3(11%)与对照组(0%)相比,在8周移植物存活中均显着改善,尽管VEGF-trap显着比抗VEGF-C(P <0.05)和sVEGFR-3(P <0.05)更有效。结论。在高风险角膜移植的临床相关模型中,该血管存在血液和淋巴管,并且在移植时开始治疗,与抗VEGF-C相比,VEGF-trap在改善长期移植物存活方面更为有效和sVEGFR-3,但与未处理的对照组相比,所有方法均可提高生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号